Xiao Xu (Hangzhou High-throughput Drug Screening Center, China) Precision targeted therapy for lung cancer: an irreversible wild-type sparing inhibitor of acquired EGFR T790M gatekeeper mutation
请使用IE浏览器访问播放
苹果系统用户点击此处播放